ProQR Therapeutics

ProQR Therapeutics is a clinical-stage biotech pioneering a novel RNA base editing platform called Axiomer. The company leverages the body's own ADAR enzyme machinery to correct RNA sequences, aiming to treat genetic disorders that are currently untreatable. Its pipeline includes both internal programs and a significant partnership with Eli Lilly, targeting a range of severe diseases. ProQR is a public company, driven by a patient-focused mission and led by a founder-CEO with a personal connection to rare disease.

Axiomer™ RNA editing platform: utilizes synthetic oligonucleotides (EDITomers) to recruit endogenous ADAR enzymes for precise, single-nucleotide RNA base editing (A-to-I conversion).

ProQR competes in the rapidly evolving RNA therapeutics space against companies developing ASOs, siRNA, and mRNA technologies, as well as other RNA and DNA editing platforms from firms like Wave Life Sciences, Alnylam, and CRISPR-focused companies. Its success depends on demonstrating superior efficacy or safety with its precise base-editing approach.